Scroll

flunitrazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	1202	1622-62-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: flunitrazepam flunidazepam fluridrazepam flunipam	A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. Molecular weight: 313.29 Formula: C16H12FN3O3 CLOGP: 1.78 LIPINSKI: 0 HAC: 6 HDO: 0 TPSA: 78.49 ALOGS: -4.56 ROTB: 2

Molecule

Description

Molfile Inchi Smiles

Synonyms:

flunitrazepam
flunidazepam
fluridrazepam
flunipam

A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.

Molecular weight: 313.29
Formula: C16H12FN3O3
CLOGP: 1.78
LIPINSKI: 0
HAC: 6
HDO: 0
TPSA: 78.49
ALOGS: -4.56
ROTB: 2

Drug dosage:

Dose	Unit	Route
1	mg	O
1	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.11 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	80 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.17 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	25 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1976	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	141.30	26.21	75	3770	74077	63411100
Neuroleptic malignant syndrome	125.09	26.21	41	3804	12015	63473162
Altered state of consciousness	112.40	26.21	46	3799	25184	63459993
Overdose	103.65	26.21	72	3773	115006	63370171
Suicide attempt	97.64	26.21	55	3790	60863	63424314
Salivary hypersecretion	87.35	26.21	28	3817	7638	63477539
Hepatic function abnormal	71.84	26.21	38	3807	37104	63448073
Psychiatric symptom	63.30	26.21	20	3825	5203	63479974
Extrapyramidal disorder	61.79	26.21	25	3820	13259	63471918
Toxicity to various agents	53.32	26.21	70	3775	247180	63237997
Loss of consciousness	52.67	26.21	49	3796	118072	63367105
Pneumonia aspiration	52.09	26.21	30	3815	34510	63450667
Blood creatine phosphokinase increased	50.12	26.21	28	3817	30402	63454775
Parkinsonism	49.77	26.21	20	3825	10419	63474758
Electrocardiogram QT prolonged	46.02	26.21	34	3811	59496	63425681
Drowning	42.42	26.21	9	3836	484	63484693
Hypothermia	41.52	26.21	19	3826	13562	63471615
Stevens-Johnson syndrome	41.19	26.21	23	3822	24927	63460250
Delusion	40.51	26.21	18	3827	11999	63473178
Lymphocytosis	39.44	26.21	12	3833	2755	63482422
Peritoneal perforation	34.02	26.21	6	3839	120	63485057
Carcinoid tumour of the stomach	32.33	26.21	6	3839	161	63485016
Brain injury	31.87	26.21	13	3832	7030	63478147
White blood cell count increased	31.51	26.21	25	3820	48536	63436641
Malignant catatonia	31.25	26.21	6	3839	194	63484983
Lip erosion	31.19	26.21	8	3837	985	63484192
Pyrexia	30.39	26.21	79	3766	470399	63014778
Electrocardiogram J wave abnormal	30.14	26.21	4	3841	9	63485168
Respiratory depression	29.26	26.21	15	3830	13700	63471477
Toxic epidermal necrolysis	27.89	26.21	18	3827	25316	63459861
Pain	26.98	26.21	6	3839	740622	62744555
Water intoxication	26.71	26.21	6	3839	421	63484756
Aspiration	26.48	26.21	13	3832	10838	63474339
Cerebral infarction	26.36	26.21	17	3828	23876	63461301

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	123.55	20.45	54	4057	17880	34934940
Hepatic function abnormal	77.71	20.45	54	4057	44309	34908511
Altered state of consciousness	76.27	20.45	42	4069	22851	34929969
Pneumonia aspiration	71.03	20.45	50	4061	41853	34910967
Rhabdomyolysis	69.12	20.45	60	4051	68103	34884717
Salivary hypersecretion	56.15	20.45	25	4086	8619	34944201
Asphyxia	55.00	20.45	23	4088	6812	34946008
Blood creatine phosphokinase increased	52.67	20.45	43	4068	44814	34908006
Water intoxication	42.98	20.45	10	4101	418	34952402
Overdose	42.69	20.45	53	4058	91006	34861814
Lymphocyte percentage increased	38.24	20.45	8	4103	203	34952617
Toxicity to various agents	38.09	20.45	77	4034	200285	34752535
White blood cell count increased	37.23	20.45	34	4077	41117	34911703
Suicide attempt	36.72	20.45	33	4078	39083	34913737
Delusion	36.15	20.45	21	4090	12614	34940206
Parkinsonism	35.81	20.45	18	4093	8120	34944700
Intentional overdose	35.50	20.45	34	4077	43640	34909180
Sciatic nerve neuropathy	33.91	20.45	6	4105	60	34952760
Psychiatric symptom	32.27	20.45	13	4098	3500	34949320
Adrenergic syndrome	31.31	20.45	6	4105	96	34952724
Stupor	31.12	20.45	12	4099	2879	34949941
Sciatic nerve injury	31.02	20.45	6	4105	101	34952719
Polydipsia	27.60	20.45	12	4099	3903	34948917
Neonatal asphyxia	23.85	20.45	6	4105	349	34952471
Circulatory collapse	22.24	20.45	19	4092	21019	34931801
Persecutory delusion	21.82	20.45	9	4102	2571	34950249
Somnolence	21.39	20.45	43	4068	111073	34841747
Hyperthermia	21.16	20.45	14	4097	10563	34942257

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	238.86	20.56	93	7765	27466	79709064
Altered state of consciousness	170.03	20.56	84	7774	43738	79692792
Hepatic function abnormal	142.38	20.56	89	7769	73018	79663512
Salivary hypersecretion	141.10	20.56	53	7805	14171	79722359
Intentional overdose	127.89	20.56	96	7762	105864	79630666
Pneumonia aspiration	114.19	20.56	75	7783	66892	79669638
Suicide attempt	104.19	20.56	77	7781	82855	79653675
Overdose	103.27	20.56	108	7750	184098	79552432
Psychiatric symptom	95.24	20.56	33	7825	7002	79729528
Blood creatine phosphokinase increased	93.59	20.56	66	7792	66024	79670506
Rhabdomyolysis	91.42	20.56	78	7780	103053	79633477
Parkinsonism	80.15	20.56	37	7821	16547	79719983
Delusion	78.70	20.56	39	7819	20384	79716146
White blood cell count increased	71.38	20.56	59	7799	74574	79661956
Extrapyramidal disorder	58.14	20.56	33	7825	22646	79713884
Water intoxication	53.89	20.56	13	7845	761	79735769
Toxicity to various agents	53.59	20.56	124	7734	421416	79315114
Asphyxia	46.99	20.56	23	7835	11697	79724833
Cerebral infarction	41.35	20.56	35	7823	45641	79690889
Dyspnoea	40.49	20.56	17	7841	857008	78879522
Pyrexia	40.14	20.56	152	7706	678557	79057973
Pain	38.32	20.56	11	7847	703791	79032739
Stupor	35.29	20.56	16	7842	6856	79729674
Lymphocyte percentage increased	34.55	20.56	9	7849	720	79735810
Depressed level of consciousness	32.94	20.56	44	7814	96608	79639922
Liver disorder	32.75	20.56	38	7820	72379	79664151
Hallucination, auditory	32.39	20.56	22	7836	20671	79715859
Electrocardiogram QT prolonged	32.11	20.56	42	7816	90344	79646186
Lip erosion	31.91	20.56	10	7848	1550	79734980
Loss of consciousness	31.40	20.56	58	7800	167885	79568645
Sudden death	30.72	20.56	22	7836	22489	79714041
Schizophrenia	30.51	20.56	19	7839	15421	79721109
Ileus paralytic	30.18	20.56	16	7842	9604	79726926
Adrenergic syndrome	29.86	20.56	6	7852	149	79736381
Polydipsia	29.62	20.56	14	7844	6591	79729939
Peritoneal perforation	29.10	20.56	6	7852	170	79736360
Carcinoid tumour of the stomach	28.36	20.56	6	7852	193	79736337
Hypothermia	28.25	20.56	21	7837	22725	79713805
Aspiration	28.20	20.56	20	7838	20138	79716392
Electrocardiogram J wave abnormal	28.19	20.56	4	7854	9	79736521
Neutrophil count increased	27.58	20.56	23	7835	29373	79707157
Lymphocytosis	27.54	20.56	12	7846	4681	79731849
Stevens-Johnson syndrome	27.49	20.56	26	7832	39140	79697390
Blood lactate dehydrogenase increased	27.49	20.56	26	7832	39144	79697386
Heat illness	26.75	20.56	7	7851	570	79735960
Fatigue	26.18	20.56	32	7826	929695	78806835
Somnolence	25.68	20.56	66	7792	238915	79497615
Brain injury	24.87	20.56	15	7843	11502	79725028
Brain oedema	24.18	20.56	20	7838	25243	79711287
Glucose tolerance impaired	24.11	20.56	13	7845	8071	79728459
Persecutory delusion	23.86	20.56	11	7847	4898	79731632
Restlessness	23.75	20.56	26	7832	46466	79690064
Sciatic nerve neuropathy	23.55	20.56	6	7852	440	79736090
Arthralgia	22.97	20.56	14	7844	571789	79164741
White blood cell count decreased	22.32	20.56	54	7804	188234	79548296
Sciatic nerve injury	22.08	20.56	6	7852	565	79735965
Suicidal ideation	21.89	20.56	32	7826	76308	79660222
Asthenia	21.29	20.56	12	7846	511677	79224853
Neutrophil percentage increased	21.21	20.56	10	7848	4679	79731851
Seizure	21.16	20.56	53	7805	188781	79547749
Pain in extremity	21.12	20.56	5	7853	364533	79371997
Withdrawal syndrome	21.12	20.56	19	7839	26835	79709695

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CD03	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:91016	GABAA receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.89	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Gamma-aminobutyric acid receptor subunit alpha-1	Ion channel	P14867	GBRA1_HUMAN	ALLOSTERIC MODULATOR	Ki	8.28	IUPHAR	IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-2	Ion channel	P47869	GBRA2_HUMAN	ALLOSTERIC MODULATOR	Ki	8.28	IUPHAR	IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-3	Ion channel	P34903	GBRA3_HUMAN	ALLOSTERIC MODULATOR	Ki	7.80	IUPHAR	IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-5	Ion channel	P31644	GBRA5_HUMAN	ALLOSTERIC MODULATOR	Ki	8.26	IUPHAR	IUPHAR
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN		Ki	8.70	WOMBAT-PK
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN		Ki	8.70	WOMBAT-PK
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN		Ki	8.35	WOMBAT-PK
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN		Ki	8.84	WOMBAT-PK
GABA-A receptor alpha-1/beta-2/gamma-3	Ion channel	P14867 P47870 Q99928	GBRA1_HUMAN GBRB2_HUMAN GBRG3_HUMAN		Ki	7.46	WOMBAT-PK
GABA-A receptor alpha-1/beta-3/gamma-2	Ion channel	P14867 P18507 P28472	GBRA1_HUMAN GBRG2_HUMAN GBRB3_HUMAN		Ki	8.47	WOMBAT-PK
GABA A receptor alpha-3/beta-2/gamma-2	Ion channel	P18507 P34903 P47870	GBRG2_HUMAN GBRA3_HUMAN GBRB2_HUMAN		Ki	8.82	WOMBAT-PK
GABA A receptor alpha-3/beta-2/gamma-3	Ion channel	P34903 P47870 Q99928	GBRA3_HUMAN GBRB2_HUMAN GBRG3_HUMAN		Ki	7.50	WOMBAT-PK
GABA A receptor alpha-5/beta-3/gamma-3	Ion channel	P28472 P31644 Q99928	GBRB3_HUMAN GBRA5_HUMAN GBRG3_HUMAN		Ki	8.42	WOMBAT-PK
GABA A receptor alpha-5/beta-2/gamma-2	Ion channel	P18507 P31644 P47870	GBRG2_HUMAN GBRA5_HUMAN GBRB2_HUMAN		Ki	9	WOMBAT-PK
GABA A receptor alpha-5/beta-2/gamma-3	Ion channel	P31644 P47870 Q99928	GBRA5_HUMAN GBRB2_HUMAN GBRG3_HUMAN		Ki	8.42	WOMBAT-PK
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		IC50	8.82	CHEMBL

External reference:

ID	Source
N0000166924	NUI
D01230	KEGG_DRUG
C0016296	UMLSCUI
CHEBI:31622	CHEBI
CHEMBL13280	ChEMBL_ID
DB01544	DRUGBANK_ID
D005445	MESH_DESCRIPTOR_UI
3380	PUBCHEM_CID
4193	IUPHAR_LIGAND_ID
2951	INN_ID
620X0222FQ	UNII
4460	RXNORM
004091	NDDF
387573007	SNOMEDCT_US
96237009	SNOMEDCT_US

Pharmaceutical products:

None